July 2009 Volume 5 Number 7
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=63&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=47&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=68&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 3.812*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Immunology & Cell Biology
Accepting Article Submissions
SUBMIT TODAY!
Spanning the breadth of immunology with a particular emphasis on the
cell biology of the immune system, Immunology & Cell Biology (ICB)
offers an outlet in which to publish your next article.
Topics of particular interest include: cellular immunology, tumour
immunology, immunopathology, immunotherapy and immunogenetics.
Immunology & Cell Biology publishes many article types including
Outstanding Observations and Theoretical Articles.
Review the Author Benefits and Submit today.
http://links.ealert.nature.com/ctt?kn=76&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
=====================================================================
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Infectious disease: T-cell subset links anti-TNF response and TB risk
p353 | doi:10.1038/nrrheum.2009.115
http://links.ealert.nature.com/ctt?kn=91&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Stem cells: Exposing gaps in our knowledge of stem cell therapy
p354 | doi:10.1038/nrrheum.2009.109
http://links.ealert.nature.com/ctt?kn=81&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Connective tissue diseases: Is epigenetic modification the future of
antifibrotic therapy?
p354 | doi:10.1038/nrrheum.2009.110
http://links.ealert.nature.com/ctt?kn=62&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
B-cell repletion studies in RA
p355 | doi:10.1038/nrrheum.2009.111
http://links.ealert.nature.com/ctt?kn=4&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Inflammatory myopathies: Intravenous immunoglobulin for myositis-associated
lung disease?
p355 | doi:10.1038/nrrheum.2009.112
http://links.ealert.nature.com/ctt?kn=33&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Connective tissue diseases: Oral anti-CD3 antibodies for SLE
p355 | doi:10.1038/nrrheum.2009.114
http://links.ealert.nature.com/ctt?kn=55&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Therapy: Resistance to adalimumab: is it predictable?
p356 | doi:10.1038/nrrheum.2009.116
http://links.ealert.nature.com/ctt?kn=5&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
IN BRIEF
Pain | Complementary and alternative therapy | Bone diseases | Rheumatoid
arthritis
p356 | doi:10.1038/nrrheum.2009.117
http://links.ealert.nature.com/ctt?kn=61&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Connective tissue diseases: Immunosuppressive therapy in SSc: what is
the target?
Francesco Boin and Fredrick Wigley
p357 | doi:10.1038/nrrheum.2009.108
Despite a lack of definitive evidence supporting their efficacy, nonselective
immunosuppressive drugs are frequently prescribed for patients with systemic
sclerosis (SSc). An analysis of data collected for a German registry
provides a review of their experience with the use of these medications.
Article: http://links.ealert.nature.com/ctt?kn=70&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Osteoarthritis: Hyaluronic acid is not effective in symptomatic hip OA
David J. Hunter
p359 | doi:10.1038/nrrheum.2009.119
Consistent with evidence from trials in osteoarthritis of the knee, the
results of a randomized controlled trial demonstrate that, for symptomatic
hip osteoarthritis, a single intra-articular injection of hyaluronic acid
is no better than placebo at alleviating pain.
http://links.ealert.nature.com/ctt?kn=16&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Connective tissue diseases: Is combined oral contraceptive use linked
to SLE incidence?
Chi Chiu Mok
p360 | doi:10.1038/nrrheum.2009.118
The link between exposure to exogenous estrogen and the incidence of
systemic lupus erythematosus is controversial, but new data suggest that
the use of combined oral contraceptives could increase the risk of developing
the disease.
Article: http://links.ealert.nature.com/ctt?kn=94&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?
Tim Bongartz and Robert Orenstein
p361 | doi:10.1038/nrrheum.2009.120
Several studies have shown that tumor necrosis factor (TNF) inhibitors
are associated with an overall increased risk of serious infections
compared with standard immunosuppressive regimens in patients with
rheumatoid arthritis (RA). A study by Strangfeld et al. adds specificity
by showing a moderately increased risk of herpes zoster in patients
receiving anti-TNF antibody treatment, and raises the question of whether
live zoster vaccines should be utilized in this patient group.
http://links.ealert.nature.com/ctt?kn=6&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Osteoarthritis: A single injection of anakinra for treating knee OA?
Johanne Martel-Pelletier and Jean-Pierre Pelletier
p363 | doi:10.1038/nrrheum.2009.121
According to a study by Chevalier and colleagues, a single intra-articular
injection of anakinra is no more effective than placebo for treating the
symptoms of knee osteoarthritis (OA). This result, however, should not
deter future investigations of this agent for the treatment of patients
with symptomatic knee OA.
http://links.ealert.nature.com/ctt?kn=35&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Fat targets for skeletal health
Masanobu Kawai, Maureen J. Devlin and Clifford J. Rosen
Published online: 26 May 2009
p365 | doi:10.1038/nrrheum.2009.102
The homeostatic processes of adipogenesis and osteoblastogenesis are
tightly linked, as discussed in this Review. Research into the bone-fat
network has led to the elucidation of pathways that could be
pharmacologically targeted in an attempt to enhance bone mass and reduce
osteoporotic fracture risk.
Abstract: http://links.ealert.nature.com/ctt?kn=39&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=50&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Hierarchical microimaging of bone structure and function
Ralph Muller
p373 | doi:10.1038/nrrheum.2009.107
The use of high-resolution imaging techniques will lead to a better
understanding of the relative contribution of the different hierarchical
levels to bone competence. Such information could help improve predictions
of fracture risk, clarify the pathophysiology of skeletal diseases, and
define the response to therapy. This Review focuses on three-dimensional
approaches to hierarchical biomechanical imaging in the study of
microstructural and ultrastructural bone failure.
Abstract: http://links.ealert.nature.com/ctt?kn=84&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=89&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Management of RA medications in pregnant patients
Monika Ostensen and Frauke Forger
Published online: 09 June 2009
p382 | doi:10.1038/nrrheum.2009.103
The treatment strategy for a patient with rheumatoid arthritis who plans
to conceive or is already pregnant must be tailored according to not
only disease activity but also which drugs are compatible with pregnancy.
The safety of various therapeutic agents during pregnancy is discussed
in this Review, as well as issues of handling inadvertent exposure to
potentially fetotoxic drugs and managing flares of disease activity during
pregnancy.
Abstract: http://links.ealert.nature.com/ctt?kn=30&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=58&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases
Farida Djouad, Carine Bouffi, Soufiane Ghannam, Daniele Noel and Christian
Jorgensen
p392 | doi:10.1038/nrrheum.2009.104
Mesenchymal stem cells (MSCs) are able to differentiate into chondrocytes,
osteoblasts and adipocytes. As well as their potential use in tissue
engineering, however, MSCs also potently modulate immune responses,
exhibit healing capacities, improve angiogenesis and prevent fibrosis,
at least partly by secreting several cytokines and growth factors.
Abstract: http://links.ealert.nature.com/ctt?kn=26&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
The socioeconomic burden of SLE
Chak Sing Lau and Anselm Mak
Published online: 09 June 2009
p400 | doi:10.1038/nrrheum.2009.106
Although major improvements have been made in the management of systemic
lupus erythematosus, the numerous burdens associated with long-term
disease have a significant impact both on individual patients and
society as a whole.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=19&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Preventing and treating biologic-associated opportunistic infections
Kevin L. Winthrop and Tom Chiller
p405 | doi:10.1038/nrrheum.2009.105
Owing to the critical role of tumor necrosis factor in host immunity,
patients receiving tumor necrosis factor inhibitors for the treatment
of autoimmune disorders are at significantly increased risk of infection
from a variety of pathogens. The authors review the evidence and provide
expert opinion on how best to prevent opportunistic infections in this
setting.
Abstract: http://links.ealert.nature.com/ctt?kn=69&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Reviews Goes Clinical!
In April 2009, Nature Clinical Practice Rheumatologywas completely redesigned
and became Nature Reviews Rheumatology, bringing all the qualities of the
top-ranked* life science review series to theclinical sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=74&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
*2008 Journal Citation Report (Thomson Reuters, 2009)
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=34&m=33479515&r=MTc2NDQ4MTc5OAS2&b=2&j=NTIzNjk5NzES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
